Tags

Type your tag names separated by a space and hit enter

How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice?
Kardiol Pol 2018; 76(8):1217-1223KP

Abstract

There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observational studies, ran-domised trials, and meta-analyses. The relationship between statin use and new-onset type 2 diabetes is associated with statin potency and dose. It seems also to be stronger if the lowering effect is stronger and the low-density lipoprotein cholesterol level achieved is lower. The mechanisms underlying the development of diabetes in statin-treated patients are not completely understood. Generally, the increased insulin resistance and decreased insulin secretion are taken into account. However, it should be kept in mind that the cardiovascular risk reduction effect of statins outweighs the harm related to diabetes induc-tion. The patients at risk of diabetes development should be monitored with regard to the parameters of glucose metabolism. The introduction of preventive lifestyle modifications to prevent diabetes is recommended. New-onset diabetes should be managed according to the guidelines.

Authors+Show Affiliations

Instytut Żywności i Żywienia. barbara.cybulska@wp.pl.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30067279

Citation

Cybulska, Barbara, and Longina Kłosiewicz-Latoszek. "How Do We Know That Statins Are Diabetogenic, and Why? Is It an Important Issue in the Clinical Practice?" Kardiologia Polska, vol. 76, no. 8, 2018, pp. 1217-1223.
Cybulska B, Kłosiewicz-Latoszek L. How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice? Kardiol Pol. 2018;76(8):1217-1223.
Cybulska, B., & Kłosiewicz-Latoszek, L. (2018). How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice? Kardiologia Polska, 76(8), pp. 1217-1223. doi:10.5603/KP.a2018.0150.
Cybulska B, Kłosiewicz-Latoszek L. How Do We Know That Statins Are Diabetogenic, and Why? Is It an Important Issue in the Clinical Practice. Kardiol Pol. 2018;76(8):1217-1223. PubMed PMID: 30067279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice? AU - Cybulska,Barbara, AU - Kłosiewicz-Latoszek,Longina, Y1 - 2018/08/01/ PY - 2018/04/13/received PY - 2018/07/10/accepted PY - 2018/06/08/revised PY - 2018/8/2/pubmed PY - 2019/1/1/medline PY - 2018/8/2/entrez KW - diabetogenic effect KW - mechanisms KW - observational studies KW - randomised trials KW - recommendations KW - statins SP - 1217 EP - 1223 JF - Kardiologia polska JO - Kardiol Pol VL - 76 IS - 8 N2 - There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observational studies, ran-domised trials, and meta-analyses. The relationship between statin use and new-onset type 2 diabetes is associated with statin potency and dose. It seems also to be stronger if the lowering effect is stronger and the low-density lipoprotein cholesterol level achieved is lower. The mechanisms underlying the development of diabetes in statin-treated patients are not completely understood. Generally, the increased insulin resistance and decreased insulin secretion are taken into account. However, it should be kept in mind that the cardiovascular risk reduction effect of statins outweighs the harm related to diabetes induc-tion. The patients at risk of diabetes development should be monitored with regard to the parameters of glucose metabolism. The introduction of preventive lifestyle modifications to prevent diabetes is recommended. New-onset diabetes should be managed according to the guidelines. SN - 1897-4279 UR - https://www.unboundmedicine.com/medline/citation/30067279/How_do_we_know_that_statins_are_diabetogenic_and_why_Is_it_an_important_issue_in_the_clinical_practice L2 - https://doi.org/10.5603/KP.a2018.0150 DB - PRIME DP - Unbound Medicine ER -